Applying the Cytyc Formula to Breast Cancer

01 Nov 2001

With its acquisition of Pro-Duct Health, Cytyc is hoping to transfer its very successful performance with the ThinPrep Pap Test to the field of ductal lavage for breast cancer risk assessment. Cytyc is paying $167.5 million for Pro-Duct, which has sales of less than $1 million. But Cytyc believes ductal lavage represents a multi-billion dollar opportunity with no direct competition. Physicians are excited about the procedure--although they caution a lot of data needs to be compiled to determine the utility of information provided by ductal lavage.

With the recently announced purchase of Pro-Duct Health Inc. , Cytyc Corp. hopes to bring its well-honed expertise at building markets to breast cancer risk assessment, and to leverage the capabilities of its core ThinPrep liquid cytology technology [See Deal]. In the five years since it got FDA approval for ThinPrep, the company has paved the way for its technology to replace the conventional Pap smear, the gold standard in cervical cancer screening. ThinPrep is now used in 50% of all cervical cancer screening procedures in the US, allowing Cytyc to grow rapidly from a miniscule start-up to a corporation with annual revenues of more than $200 million.

Clearly, Cytyc is hoping for a repeat performance with ductal lavage, Pro-Duct's core technology. Sometimes referred to as a Pap smear for the breast, ductal lavage is a minimally invasive...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

20 May 2025

• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

16 May 2025

• By Jo Shorthouse

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

15 May 2025

• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

13 May 2025

• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

20 May 2025

• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.